Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Dr. Harry Quon is an associate professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also holds appointments in oncology and in otolaryngology - head and neck surgery. His area of clinical expertise is radiation treatment for head and neck cancers. He serves as the co-director of the Johns Hopkins Head and Neck Cancer Multidisciplinary Clinic. Dr. Quon received his M.D. from the University of Toronto Institute of Medical Science. He completed his residency at the Princess Margaret Hospital in Ontario and performed a fellowship in radiation oncology at the Princess Margaret Hospital and the Beth Israel Medical Center. Make A Gift. Dr. Quon is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Dry Mouth, Gastrostomy, and Prostatectomy.

Dr. Julie Lange is an assistant professor of surgery, dermatology and oncology at the Johns Hopkins University School of Medicine. Dr. Lange was one of the original members of the Johns Hopkins melanoma group when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Johns Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique. Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. She has particular interest in melanoma at extremes of age, and in the factors associated with variance in melanoma care. Dr. Lange has published the largest study of melanoma in children, adolescents and young adults. She recognizes that melanoma in the older patient is a growing epidemic and has investigated the socioeconomic, demographic and healthcare factors that influence the treatment of melanoma in older persons. Dr. Lange is a member of the melanoma panel of the National Comprehensive Cancer Network, a group that annually evaluates and revises national treatment guidelines for melanoma. In 2015, she was inducted for her work into the Miller-Coulson Academy of Clinical Excellence, which recognizes outstanding clinicians at Johns Hopkins based on a number of factors, including communication and interpersonal skills, professionalism and humanism, a scholarly approach to clinical practice, and a passion for patient care. Dr. Lange is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphadenectomy.

Dr. John Migaly is a distinguished colorectal surgeon and Chief of the Division of Colorectal Surgery/Ravitch Division at Johns Hopkins Medicine. He specializes in the treatment of colorectal cancer, inflammatory bowel disease, and other benign and complex colorectal conditions. Dr. Migaly is committed to providing advanced, patient-centered care, often using minimally invasive techniques including laparoscopic and robotic surgery, to help reduce recovery time and improve outcomes. Dr. Migaly comes to Johns Hopkins Medicine from the Duke University School of Medicine, serving from 2008-2024 on the surgery faculty treating patients primarily through the Duke Cancer Institute. He was elevated to Program Director of the General Surgery Residency in 2012, and subsequently served as Vice Chair of Education until 2024. His work was critical to the success of the undergraduate, graduate, and continuing medical education missions at Duke Surgery. Dr. Migaly earned his B.A. in Biochemistry from New York University and his medical degree from the New York University School of Medicine. He completed surgical residency and a research fellowship at Temple University Health Sciences Center, and colorectal surgery fellowship at Cleveland Clinic Florida. Dr. Migaly’s career has been marked not only by a complex and high-volume clinical colon and rectal surgery practice, but also a commitment to research and education, supported by greater than 200 publications, book chapters, and presentations. His research is centered around improving practice patterns and outcomes in colorectal cancer care and recovery. His leadership and dedication to advancing the field of colorectal surgery is evident through his service on committees that shape how colorectal care is delivered nationally, via his past and present service on the Program Committee, the Clinical Practice Guidelines Committee and the Diversity and Inclusion Committee of the American Society of Colon and Rectal Surgeons. Videos John Migaly, M.D.Chief of Colorectal Surgery"". Dr. Migaly is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Anal Cancer, Colostomy, and Ileostomy.

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.

Colleen McCormick, M.D., M.P.H., is an assistant professor in the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine in Baltimore. Her areas of clinical expertise include gynecologic oncology with a focus on cervical and endometrial cancers, complex cancer cases and surgery for gynecologic cancers. A Baltimore native, Dr. McCormick received her undergraduate degree from Earlham College in Richmond, Virginia. Her advanced degrees include a doctorate in medicine and a Master of Public Health from Johns Hopkins. Dr. McCormick completed her residency as well as the F.J. Montz Fellowship in Gynecologic Oncology at The Johns Hopkins Hospital. She has significant clinical experience, initially in Portland, Oregon, where she was the medical director at Legacy Gynecologic Oncology. She was most recently at the University of New Mexico before returning home to Johns Hopkins and Baltimore. Her research interests include clinical trial programs, focusing on increasing diversity and inclusion in clinical trials. Deeply invested in patient experience, she recently served as a patient safety officer at the University of New Mexico, and she has researched practitioner and patient perspectives regarding endometrial cancer care. She has additional training in palliative care and genetic counseling, and she strongly values being able to accompany patients through their entire cancer journey. Dr. McCormick is a published author and has been invited to lecture both regionally and nationally. Dr. Mccormick is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Ovarian Cancer, Ovarian Carcinosarcoma, and Bladder Reconstruction.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Neil Rosenshein is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Rosenshein is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Angiomyoma, Uterine Fibroids, Ovarian Carcinosarcoma, Ureteroscopy, and Vaginectomy. Dr. Rosenshein is currently accepting new patients.

Teresa Diaz-Montes is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Diaz-Montes is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Vulvar Cancer, Hysterectomy, and Ureteroscopy. Dr. Diaz-Montes is currently accepting new patients.

Fong W. Liu, M.D., M.P.H., is an assistant professor at the Johns Hopkins University School of Medicine. Her clinical expertise includes gynecologic oncology and general gynecology and obstetrics. Dr. Liu earned her Doctor of Medicine degree from the University of Alabama. She completed her residency in obstetrics and gynecology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Liu then went on to complete her fellowship in gynecologic oncology at the University of California, Irvine. Prior to joining Johns Hopkins, Dr. Liu served as an instructor in the department of obstetrics and gynecology at Beth Israel Deaconess Medical Center. Dr. Liu is also a gynecologic oncologist at the Sandra and Malcolm Berman Cancer Institute at GBMC. Dr. Liu is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Endometrial Cancer, Oophorectomy, and Hernia Surgery.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as a Distinguished provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dwight Im is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Im is rated as an Advanced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Rectocele, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Oophorectomy. Dr. Im is currently accepting new patients.

Hyung Ryu is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Ryu is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Hernia Surgery. Dr. Ryu is currently accepting new patients.

Jeffrey Wolf is an Otolaryngologist in Baltimore, Maryland. Dr. Wolf is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Acinic Cell Carcinoma of Salivary Glands, Thyroidectomy, and Gastrostomy. Dr. Wolf is currently accepting new patients.

Rodney Taylor is an Otolaryngologist in Baltimore, Maryland. Dr. Taylor is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Teratocarcinosarcoma, Olfactory Neuroblastoma, Sinus Cancer, Laryngectomy, and Tissue Biopsy.

Gautam Rao is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Baltimore, Maryland. Dr. Rao is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Hysterectomy. Dr. Rao is currently accepting new patients.

Mark Mishra is a Radiation Oncologist in Baltimore, Maryland. Dr. Mishra is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Metastatic Brain Tumor, Astrocytoma, Brain Tumor, Meningioma, and Prostatectomy. Dr. Mishra is currently accepting new patients.

Mohan Suntha is a Radiation Oncologist in Baltimore, Maryland. Dr. Suntha is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Tongue Cancer, Oral Squamous Cell Carcinoma, Laryngeal Cancer, and Throat Cancer. Dr. Suntha is currently accepting new patients.

Ranee Mehra is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mehra is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Tongue Cancer, and Glossectomy. Dr. Mehra is currently accepting new patients.

Abhishek Kalla is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Kalla is rated as an Experienced provider by MediFind in the treatment of Eccrine Porocarcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Pancreatic Cancer, Familial Pancreatic Cancer, and Prostate Cancer. Dr. Kalla is currently accepting new patients.